# US 10,370,451 B2 · Preventive or therapeutic agent for inflammatory disease > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,370,451 B2 - Document ID: US10370451B2 - Status: Granted - Kind: B2 - Application number: 14/785,844 - Filed: 2013-10-22 - Published: 2016-06-30 - Granted: 2019-08-06 - Earliest claimed: 2013-04-22 - Assignees: The University of Tokyo - Applicants: The University of Tokyo - Inventors: Kensuke Miyake; Atsuo Kanno; Yuji Motoi; Masahiro Onji - Web page: https://patentgrep.com/patent/US10370451B2 ## CPC - C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere} - A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines} - A61P 17/06: Antipsoriatics - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 37/02: Immunomodulators - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K 2039/505: {comprising antibodies} - C07K 16/28: against receptors, cell surface antigens or cell surface determinants - C07K 16/2866: {against receptors for cytokines, lymphokines, interferons} - C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1 - C07K 2317/515: Complete light chain, i.e. VL + CL - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract An object of the present invention is to provide a highly-safe and highly-specific preventive or therapeutic agent for inflammatory diseases targeting a TLR7 or TLR9 molecule. The present invention provides a preventive or therapeutic agent for inflammatory diseases containing an anti-TLR7 antibody or anti-TLR9 antibody. ## Claims ### Claim 1 An anti-TLR7-antibody (anti-Toll-like receptor 7) selected from the group consisting of: (i) an antibody containing a heavy chain CDR1 having the amino acid sequence represented by SEQ ID NO: 3, a heavy chain CDR2 having the amino acid sequence represented by SEQ ID NO: 4, a heavy chain CDR3 having the amino acid sequence represented by SEQ ID NO: 5, a light chain CDR1 having the amino acid sequence represented by SEQ ID NO: 6, a light chain CDR2 having the amino acid sequence represented by SEQ ID NO: 7, and a light chain CDR3 having the amino acid sequence represented by SEQ ID NO: 8; and (ii) an antibody containing a heavy chain having the amino acid sequence represented by SEQ ID NO: 9 and a light chain having the amino acid sequence represented by SEQ ID NO: 10. ### Claim 2 (depends on 1) A method of treating a TLR7-dependent inflammatory disease comprising a step of administering a therapeutic agent to a subject, the therapeutic agent comprising an anti-TLR7 (anti-Toll-like receptor 7) antibody according to claim 1. ### Claim 3 (depends on 2) The method of treating the inflammatory disease according to claim 2, wherein the anti-TLR7 antibody is an antibody containing a heavy chain CDR1 having the amino acid sequence represented by SEQ ID NO: 3, a heavy chain CDR2 having the amino acid sequence represented by SEQ ID NO: 4, a heavy chain CDR3 having the amino acid sequence represented by SEQ ID NO: 5, a light chain CDR1 having the amino acid sequence represented by SEQ ID NO: 6, a light chain CDR2 having the amino acid sequence represented by SEQ ID NO: 7, and a light chain CDR3 having the amino acid sequence represented by SEQ ID NO: 8. ### Claim 4 (depends on 2) The method of treating the TLR7-dependent inflammatory disease according to claim 2, wherein the TLR7 antibody is an antibody containing a heavy chain having the amino acid sequence represented by SEQ ID NO: 9 and a light chain having the amino acid sequence represented by SEQ ID NO: 10. ### Claim 5 (depends on 2) The method of treating the TLR7-dependent inflammatory disease according to claim 2, wherein the TLR7-dependent inflammatory disease is an autoimmune disease. ### Claim 6 (depends on 5) The method of treating the TLR7-dependent inflammatory disease according to claim 5, wherein the autoimmune disease is systemic lupus erythematosus or psoriasis.